AEON Biopharma, Inc. (AEON) Insider Trading Activity

AMEX$0.2229+0.01 (4.71%)
Market Cap
$10.59M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
219 of 849
Rank in Industry
126 of 491

AEON Insider Trading Activity

AEON Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$243,455
1
100
Sells
$0
0
0

Related Transactions

LYNCH TIMOTHY P10 percent owner
1
$243,455
0
$0
$243,455

About AEON Biopharma, Inc.

AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal …

Insider Activity of AEON Biopharma, Inc.

Over the last 12 months, insiders at AEON Biopharma, Inc. have bought $243,455 and sold $0 worth of AEON Biopharma, Inc. stock.

On average, over the past 5 years, insiders at AEON Biopharma, Inc. have bought $164,003 and sold $73.8M worth of stock each year.

Highest buying activity among insiders over the last 12 months: LYNCH TIMOTHY P (10 percent owner) — $243,455.

The last purchase of 1,150,000 shares for transaction amount of $243,455 was made by LYNCH TIMOTHY P (10 percent owner) on 2026‑08‑19.

List of Insider Buy and Sell Transactions, AEON Biopharma, Inc.

2026-08-19PurchaseLYNCH TIMOTHY P10 percent owner
1.15M
2.7788%
$0.21
$243,455
+30.54%
2025-05-21PurchaseFISCHER JOSTdirector
60,000
0.5653%
$0.49
$29,250
+83.13%
2025-05-20PurchaseFISCHER JOSTdirector
60,000
0.5606%
$0.51
$30,360
+74.85%
2025-05-19PurchaseFISCHER JOSTdirector
50,000
0.4599%
$0.50
$24,940
+74.85%
2023-08-11Sale
Strathspey Crown Holdings Group, LLC
10 percent owner
7.38M
–
$10.00
$73.8M
-21.15%
2021-03-23SaleGLAZER CAPITAL, LLC10 percent owner
73,226
3.4019%
$10.10
$739,583
2021-03-22SaleGLAZER CAPITAL, LLC10 percent owner
100,650
4.6993%
$10.15
$1.02M
2021-03-19SaleGLAZER CAPITAL, LLC10 percent owner
11,033
0.5176%
$10.20
$112,537
2021-03-17SaleGLAZER CAPITAL, LLC10 percent owner
3,500
0.1642%
$10.20
$35,700
2021-02-25SaleGLAZER CAPITAL, LLC10 percent owner
62,356
2.9686%
$10.35
$645,385
2021-02-17SaleGLAZER CAPITAL, LLC10 percent owner
10,000
0.4899%
$10.65
$106,500
2021-01-26SaleGLAZER CAPITAL, LLC10 percent owner
10,000
0.483%
$10.50
$105,000
Total: 12
*Gray background shows transactions not older than one year

Insider Historical Profitability

77.61%
LYNCH TIMOTHY P10 percent owner
6500000
13.0305%
$1.38M10
FISCHER JOSTdirector
266785
0.5348%
$56,611.7830
+77.61%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$18,815,063
62
-6.45%
$13.7M
$1,993,425
46
-21.91%
$13.95M
$95,567,744
39
-17.01%
$10.94M
$30,257,839
29
-15.72%
$12M
$76,600
22
-38.58%
$10.49M

AEON Institutional Investors: Active Positions

Increased Positions12+63.16%1M+81.09%
Decreased Positions5-26.32%28,215-2.07%
New Positions4New39,826New
Sold Out Positions4Sold Out28,214Sold Out
Total Postitions26+36.84%2M+79.02%

AEON Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Dauntless Investment Group, Llc$1,249.009.38%1.13M00%2025-09-30
Vanguard Group Inc$109.000.82%98,568+98,568New2025-09-30
Geode Capital Management, Llc$52.000.39%47,073+26,378+127.46%2025-09-30
Blue Owl Capital Holdings Lp$47.000.35%42,35300%2025-09-30
Stonex Group Inc.$20.000.15%17,578+17,578New2025-09-30
Xtx Topco Ltd$18.000.14%16,162+16,162New2025-09-30
Jane Street Group, Llc$12.000.09%10,420+10,420New2025-09-30
Blackrock, Inc.$3.000.02%2,834-21-0.74%2025-09-30
Bank Of America Corp /De/$3.000.02%2,376-9-0.38%2025-09-30
Ubs Group Ag$1.000.01%1,192-30,408-96.23%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.